Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel + bevacizumab versus Myocet + cyclophosphamide + bevacizumab in first-line HER2-negative metastatic breast cancer
2011-006176-39Phase 2Completed
- Sponsor
- GOIM
- Start
- Jun 2012
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Paclitaxel + bevacizumab with Myocet + cyclophosphamide + bevacizumab (2 arms). Primary endpoint: Objective response rate. Started Jun 2012; status: completed.
02
Drugs
paclitaxeldoxorubicincyclophosphamidebevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-006176-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006176-39.